Introduction
The use of glaucoma drainage implants has increased in recent years, especially relative to other surgical glaucoma procedures such as trabeculectomy [1,2 •• ]. The increased utilization of drainage implants is related to a greater experience and appreciation of the efficacy of aqueous shunts, and a growing concern about late complications associated with standard filtering surgery [3] . Only a handful of glaucoma drainage implant types are commercially available and in common use. Comparisons between the various implant types are, however, difficult because most clinical data are derived from retrospective studies with different study populations, small sample size, limited follow-up, and varied criteria for defining successful outcomes. In addition, the types of glaucoma for which drainage implants are being used has expanded to include eyes with major retinal or corneal surgery and glaucomas associated with pseudophakia, aphakia, uveitis, trauma, epithelial and fibrous downgrowth, anirida, and iridocorneal endothelial syndrome. These refractory glaucoma types can be effectively managed with glaucoma drainage implants, albeit with differing levels of success that affect comparative efficacy results between the varying types of glaucoma drainage implants.
Current glaucoma drainage implants
All modern glaucoma drainage implants consist of a tube that shunts aqueous humor to an end plate (or explant) located in the equatorial region of the globe. Drainage implants differ in their design with respect to the size, shape, and material from which the end plate is constructed. They may be further subdivided into valved and nonvalved implants, depending on whether or not a valve mechanism is present that limits flow through the tube to the plate if the intraocular pressure (IOP) becomes too low. The implants currently in common use include the Ahmed glaucoma valve (New World Medical, Rancho Cucamonga, California, USA), the Baerveldt glaucoma implant (Advanced Medical Optics, Santa Ana, California, USA), the Krupin slit valve (Hood Laboratories, Pembroke, Massachusetts, USA), and the Molteno implant (Molteno Ophthalmic Limited, Dunedin, New Zealand). Fig. 1 shows these popular glaucoma drainage implants, and Table 1 reviews the major design features for each implant.
Ahmed glaucoma valve
The Ahmed glaucoma valve has a scarab-shaped end plate made of polypropylene (models S2, S3, and B1) or silicone (models FP7, FP8, and FX1). Fenestrations have been added to the plate of the silicone models. Different sizes of the Ahmed valve are available, including those with a surface area of 96 mm 2 (S3 and FP8) or 184 mm 2 (S2 and FP7). A double-plate version has a surface area of 364 mm 2 (B1 and FX1). Aqueous humor passes from the anterior chamber tube through two thin membrane-like elastomer sheets that theoretically restrict flow until a pressure of greater than 8-12 mmHg is exerted upon them.
Baerveldt glaucoma implant
The Baerveldt glaucoma implant is a nonvalved implant. The end plate is made of barium impregnated, rounded silicone with surface areas of 250-or 350-mm 2 . The plate has fenestrations, which allow fibrous bands to develop that reduce the profile of the bleb.
Krupin slit valve
The Krupin slit valve consists of an anterior chamber tube connected to an oval silastic disc with a surface area of 183 mm 2 . Alternatively, the tube end may be connected to a #220 silastic band. The distal end of the tube contains horizontal and vertical slits that function as a unidirectional and pressure-sensitive valve.
Molteno implant
The Molteno implant has a round polypropylene end plate with a surface area of 134 mm 2 for the singleplate implant and 268 mm 2 for the double-plate implant. The plates of the double-plate implant are connected by a 10 mm silicone tube.
Surgical results
Attempts at comparing the surgical results achieved with the various glaucoma drainage implants are made difficult because of differences in study populations, followup period, and criteria by which success is defined. The type of glaucoma under treatment is a major factor influencing surgical success. Tables 2-6 present surgical results reported with various drainage implants according to glaucoma type. Case series studying glaucoma drainage implants have reported success rates ranging from 22% to 78% for neovascular glaucoma [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] , 75% to 100% for uveitic glaucoma [9] [10] [11] 17, 18, 19] , 44% to 100% for developmental glaucoma [4,5,8-11,20-32, 33 • ], 50% to 88% for eyes that have undergone cataract surgery [4, 5, 8, 10, 11, 14, 15, 34, 35] , and 44% to 88% for eyes with failed glaucoma filtering surgery [4, 5, 8, 11, 15, 35] . The poorest surgical results are observed in neovascular glaucoma. As with trabeculectomy, attrition over time results in a trend toward lower success rates among studies with longer follow-up periods.
Pathophysiology
Following implantation of a glaucoma drainage device, a fibrous capsule forms around the end plate over a period of several weeks. A feature common to all glaucoma drainage implants is construction of the plate from materials to which fibroblasts cannot adhere. Aqueous humor pools in the potential space between the end plate and surrounding, nonadherent fibrous capsule when flow occurs through the anterior chamber tube. Aqueous then passes through the capsule via the process of passive diffusion and is absorbed by periocular capillaries and lymphatics. It is the fibrous capsule around the end plate that offers the major resistance to aqueous flow with drainage implants. Therefore, the degree of IOP reduction observed following glaucoma drainage implant surgery is dependent on capsular thickness and the total surface area of encapsulation. Lower postoperative IOP is expected with a thinner capsule and larger surface area of encapsulation.
Implant size and intraocular pressure reduction
The surface area of encapsulation around a glaucoma drainage implant is directly proportional to the end plate size. Therefore, the degree of IOP reduction achieved postoperatively is also directly proportional to implant size. In other words, glaucoma drainage implants with large plates produce a larger surface area of encapsulation and greater degree of pressure reduction. There is good clinical evidence to support this premise. In a prospective randomized clinical trial comparing single-plate and double-plate Molteno implants, Heuer and colleagues found a higher success rate and greater IOP reduction with the double-plate implant presumably because of its larger surface area [34] .
There appears to be an upper limit to plate size beyond which an increase in surface area may not improve pressure control, and may even detrimentally affect surgical outcome. In a prospective study comparing the 350-mm 2 and 500-mm 2 Baerveldt glaucoma implants, Lloyd et al. found no significant difference in surgical success and visual outcomes between the different implant sizes [36] . saline solution during placement of a Molteno implant. No significant IOP difference was noted between the two groups [39] . Costa et al. prospectively randomized 60 eyes with refractory glaucoma to receive intraoperative MMC or buffered saline and found no effect of the MMC on IOP lowering at 18 months [40 •• ] . No clear benefit of antifibrotic agents as adjuncts to glaucoma implant surgery has been observed, and a higher incidence of hypotony, flat anterior chambers, choroidal effusions, and conjunctival melts has been reported with their use [38, 41, 42] .
Studies comparing different implant types
Prospective randomized clinical trials comparing glaucoma drainage implants of differing size, but of the same type (that is, double-plate versus single-plate Molteno implants [34] and 350-mm 2 versus 500-mm 2 Baerveldt implant [36, 37] ) have offered important insight into the role of implant plate surface area and IOP lowering. Unfortunately, no prospective studies comparing different implant types have been reported. Current data regarding the role and efficacy of different glaucoma drainage implant designs are limited to retrospective case series, which have selection bias inherent to any retrospective study design. Differences in the familiarity of surgeons with each of the implants (that is, the number of each type used in the study), differences in the glaucoma type (that is, neovascular, uveitic, postkeratoplasty, etc.), follow-up periods, and other factors make direct comparisons in these retrospective studies difficult. In addition, some of these comparative study results for the Ahmed valve may not be valid to current practice with the change from the polypropylene to the silicone Ahmed implant by many surgeons. [48] . The double-plate Molteno was more likely to produce a lower IOP, but it also had a higher rate of hypotony.
Complications
Comparison of the various glaucoma drainage implants requires not only an assessment of their efficacy, but also an evaluation of their surgical complications. Drainage implants have similar operative and postoperative complications as encountered with trabeculectomy, but there are other unique complications associated with their use. Differences exist in the incidence of hypo-tony, diplopia, and bleb encapsulation with the glaucoma drainage implants in current use.
Hypotony
Nonvalved implants initially had a relatively high rate of postoperative hypotony until techniques were developed to temporarily restrict aqueous flow through the device until encapsulation of the end plate occurred. Methods for flow restriction with single-stage implantation include tube ligation with a polyglactin (Vicryl; Ethicon, Somerville, New Jersey, USA) or prolene suture, or tube obstruction with a collagen plug or luminal suture. Additionally, a two-stage implantation technique may be used in which the implant is attached to sclera in the first stage of the procedure, and the tube is later inserted into the anterior chamber after a period of several weeks during the second stage.
Temporary restriction of aqueous flow makes the implant nonfunctional in the immediate postoperative period. Reinstitution of medical therapy frequently provides adequate pressure reduction until the tube opens and the implant becomes functional. Tube fenestration may also be performed intraoperatively, and this technique has been shown to effectively decrease IOP in the early postoperative period with nonvalved implants [49, 50] . We prefer to fenestrate the tube with a TG-140 or TG-160 needle (Ethicon) anterior to a Vicryl ligature near the tube-plate junction, and 1-3 fenestrations are placed along the tube depending on the preoperative IOP level. Alternatively, an orphan trabeculectomy may be performed in conjunction with glaucoma drainage implant placement for early postoperative pressure control.
Diplopia
Transient diplopia is not uncommon following glaucoma drainage implant surgery, but it generally resolves as the postoperative periocular edema improves. Persistent restrictive strabismus may occur because of scarring between the rectus or oblique muscles and the implant [51] , or due to a crowding effect from a large bleb with limitation of extraocular motility [52, 53] . Although diplopia may occur with any of the drainage implants, it was particularly common following the introduction of the Baerveldt glaucoma implant [54] . The manufacturer of the Baerveldt implant subsequently discontinued the 500-mm 2 size implant and included fenestrations in the end plate, which allows the growth of fibrous bands through the plate to reduce bleb height. These design modifications have markedly reduced the incidence of diplopia with the Baerveldt glaucoma implant.
Bleb encapsulation
Failure to control IOP after glaucoma drainage implant surgery may occur secondary to encapsulation of the bleb around the end plate. This complication is analogous to an encapsulated bleb that develops after trabeculectomy, and it is generally treated in a similar fashion with antiglaucoma medications. The incidence of bleb encapsulation has been estimated to be between 40% and 80% with the Ahmed glaucoma valve, and between 20% and 30% with the Baerveldt and double-plate Molteno glaucoma implants [55 •• ] . Several possible explanations have been offered for the higher incidence of bleb encapsulation with the Ahmed glaucoma valve compared with other implants. Some authors have suggested that immediate aqueous filtration with inflammatory factors may stimulate a fibrotic response in the subconjunctival space when the Ahmed implant is used, and delayed flow with a ligated, nonvalved implant may elicit a less fibrous reaction [43] . Others have speculated that differences in the rate of bleb encapsulation may be related to the biomaterial, shape, and consistency of the end plate [56, 57] .
Future glaucoma drainage implants
Several glaucoma implants are in development, and early clinical use shows variable levels of promise. These new glaucoma implants have a similar goal of shunting aqueous fluid out of the anterior chamber and bypassing the trabecular meshwork to increase outflow and lower the IOP.
The Ex-Press Mini Glaucoma Shunt (Optonol, Neve Ilan, Israel) is a stainless steel nonvalved glaucoma drainage implant that resembles a small arrowhead. This 3mm metal device has a short shaft with a central hollow lumen that is 400 μm in external diameter (27 gauge) and shunts aqueous from the anterior chamber to an episcleral space [58] . Initially, the Ex-Press shunt was designed for implantation near the limbus through the sclera into the anterior chamber with the external plate of the shunt under a conjunctival flap, thereby producing a filtering bleb near the entry point of the Ex-Press shunt. This resulted, however, in a significant number of postoperative complications, including unacceptably high incidences of postoperative hypotony (91%), choroidal detachment (27%), and suprachoroidal hemorrhage (18%) [59] . Fewer complications were reported when the Ex-Press shunt was placed in conjunction with cataract surgery in a long-term study with a 2-year to 3-year follow-up period, although short-term surgical complications were not reported [58] . Long-term complications associated with the Ex-Press shunt included shunt erosion through the conjunctiva, and device malposition and rotation [58] .
The high early surgical complication rate with the Ex-Press shunt led to implantation of this device under a scleral flap, similar to that used for a trabeculectomy. Postoperative complication rates of hypotony, choroidal effusions, and shallow anterior chamber for this new form of a guarded filtration procedure were dramatically less than those reported with the nonguarded procedure [59,60 • ]. Although two-thirds of the patients were lost to follow-up by 2 years, the remaining one-third of the initial study patients had an average IOP reduction of 45% [60 • ]. Although implantation of the Ex-Press is a relatively quick procedure, its use in conjunction with a scleral flap (as advocated by the manufacturers) presents this as a modified trabeculectomy procedure, and more experience and long-term follow-up will determine whether the Ex-Press shunt offers any advantages over conventional trabeculectomy. . More studies and longer term follow-up will be necessary to determine how this implant will compare to the current commonly used glaucoma drainage implants.
Another aqueous shunt in clinical trials in the USA is based upon the hypothesis that changing the geometry of the aqueous shunt from a plate design, as is used by most of the commonly used current glaucoma drainage implants, to a cylindrical shape will decrease tension on the capsule surrounding the implant and lead to a thinner capsule with greater hydraulic conductivity [63] . In rabbit eye experiments, the cylindrical implant design resulted in significantly thinner blebs (20 μm compared to 222 μm for a Baerveldt implant) with eight times the hydraulic conductivity, as measured by perfusion experiments [64] . The exciting design promise of this implant is that with a decrease in the length of the cylinder, the filtration surface area can be modified to titrate and better control the IOP. Human study results should be forthcoming for this implant.
A 24 carat gold 44 μm thick plate that acts as a shunt implanted between the anterior chamber and the supraciliary space to increase uveoscleral outflow is in clinical trials in Europe. Preliminary studies with a small number of patients demonstrated greater than 40% reduction in IOP in a 14-month study period, although the types and rates of complications were not well characterized (S. Melamed, Gold micro-shunt implantation for the reduction of IOP, paper presented at American Academy of Ophthalmology Annual Meeting; October 2005; Chicago, IL, USA).
As technology improves with regard to biocompatible materials, more reliable valve features, and biochemical and molecular methods to regulate wound healing (that is, bleb thickness and encapsulation), we anticipate improved and more reliable clinical outcomes with future glaucoma drainage implants. The new nanotechnology initiative led by the National Eye Institute should lead to innovations for the control of IOP and treatment of glaucoma.
Conclusion
Several different types of glaucoma drainage implants are currently available, and all have been shown to be safe and effective in reducing IOP in glaucoma patients. A paucity of studies exists which compare different glaucoma drainage implant types, and these are all limited to retrospective case studies. The Ahmed Baerveldt Comparison (ABC) study is the first multicenter randomized clinical trial comparing different implant types and promises to yield valuable information that will guide surgical decision-making (D. Budenz, personal communication). We generally prefer the Baerveldt glaucoma implant because it optimizes surface area and ease of implantation as a single-plate implant. A Vicryl suture is used to ligate the tube at the time of implantation, and we routinely fenestrate the tube for early pressure control. We use valved implants in the rare situations where aqueous hyposecretion may be present with uncontrolled glaucoma, such as uveitic glaucoma or eyes with prior cyclodestruction. In these settings, the valve mechanism should serve to minimize the risk of postoperative hypotony.
